Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Quang X. Pham
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 1.86
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.96
Financials
Net Income
$-3.32MEBITDA
$-3.34MFree Cash Flow
$-2.23MEPS (diluted)
$-1.14Shares Outstanding (diluted)
2.91M-75.0%Operating Expenses
$3.34MCash & Debt
$2.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-13.24M | $-6.64 |
| 2024 | $0.00 | $-10.65M | $-8.73 |
| 2023 | $0.00 | $-8.36M | $-9.63 |
| 2022 | $0.00 | $-6.71M | $-8.66 |
Valuation
CVKDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Negative
… in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026.
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-1.00 per share
Typical surprise -16.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.14 vs $-1.42beat
- Thu, May 7$-1.04 vs $-1.51beat
- Tue, Mar 31$-1.41 vs $-1.17miss
- Mon, Nov 10$-1.31 vs $-1.55beat
- Mon, Aug 11$-1.87 vs $-1.60miss
- Thu, May 8$-2.09 vs $-1.64miss
Estimates and results for CVKD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CVKD officers and directors.
- Bought
- $161k
- Sold
- $1.1m
11 trades
45 trades
- Pham Quang Xsold
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·9,029 @ $3.05·$28k·Jun 26, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·2,127 @ $3.00·$6k·Jun 25, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·2,277 @ $3.20·$7k·Jun 23, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·9,167 @ $3.55·$33k·Jun 22, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·513 @ $3.16·$2k·Jun 17, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·3,613 @ $3.18·$11k·Jun 16, 2026·filing
- Pham Quang Xsolddirector, 10 percent owner, officer: Chairman, CEO and Interim CFO·3,666 @ $3.58·$13k·Jun 15, 2026·filing
42 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.